AR127945A1 - Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina - Google Patents
Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrinaInfo
- Publication number
- AR127945A1 AR127945A1 ARP220103410A ARP220103410A AR127945A1 AR 127945 A1 AR127945 A1 AR 127945A1 AR P220103410 A ARP220103410 A AR P220103410A AR P220103410 A ARP220103410 A AR P220103410A AR 127945 A1 AR127945 A1 AR 127945A1
- Authority
- AR
- Argentina
- Prior art keywords
- receptor agonist
- glp
- cyclodextrin
- pharmaceutical formulations
- amylin
- Prior art date
Links
- 229940124035 Amylin receptor agonist Drugs 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title abstract 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010033307 Overweight Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- -1 hydroxypropyl Chemical group 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
En la presente descripción se describe una formulación farmacéutica líquida que comprende un agonista del receptor de amilina, un agonista del receptor de GLP-1 y una ciclodextrina que comprende sustituciones de hidroxipropilo. Dicha coformulación puede usarse para el tratamiento médico de sujetos con sobrepeso u obesidad, con o sin comorbilidades asociadas; diabetes, con o sin comorbilidades asociadas; enfermedades cardiovasculares, esteatohepatitis no alcohólica (NASH) y deterioro cognitivo, tal como el que provoca la enfermedad de Alzheimer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2023/058317 WO2023187067A1 (en) | 2022-03-30 | 2023-03-30 | Formulation method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21214004 | 2021-12-13 | ||
EP22191564 | 2022-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR127945A1 true AR127945A1 (es) | 2024-03-13 |
Family
ID=84819844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220103410A AR127945A1 (es) | 2021-12-13 | 2022-12-13 | Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR127945A1 (es) |
TW (1) | TW202339788A (es) |
WO (1) | WO2023110833A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
US8389472B2 (en) * | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
JP2010512399A (ja) * | 2006-12-12 | 2010-04-22 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 医薬製剤及びその調製方法 |
US8575090B2 (en) | 2011-06-10 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
EP3858373A1 (en) * | 2020-01-31 | 2021-08-04 | Adocia | Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist |
TW202227474A (zh) | 2020-12-18 | 2022-07-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
-
2022
- 2022-12-13 AR ARP220103410A patent/AR127945A1/es unknown
- 2022-12-13 TW TW111147761A patent/TW202339788A/zh unknown
- 2022-12-13 WO PCT/EP2022/085558 patent/WO2023110833A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
TW202339788A (zh) | 2023-10-16 |
WO2023110833A1 (en) | 2023-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021001332A1 (es) | Agonistas de glp-1r y usos de los mismos. | |
BR112022013746A2 (pt) | Formulação aquosa de cagrilintida, formulação aquosa de semaglutida, dispositivo médico, e, combinação de dose fixa | |
CR20230330A (es) | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso | |
SV2017005539A (es) | Composiciones farmaceuticas para terapia combinada | |
BR112018008805A8 (pt) | proteínas de função dupla e composição farmacêutica que compreende a mesma | |
BR112021022335A2 (pt) | Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer | |
BR112015010203A8 (pt) | composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina | |
BR112022003589A2 (pt) | Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo | |
CO2023008866A2 (es) | Coagonistas de los receptores de glp-1 y amilina | |
MX2022015500A (es) | Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico. | |
PH12019502655A1 (en) | Acylated insulin compound | |
Forbes et al. | Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides | |
BR112014031649A2 (pt) | composto representado pela fórmula 1 tendo a enzima inibidora de atividade 11b-hsd1; método para sua produção e composição farmacêutica contendo o mesmo como ingrediente ativo | |
BR112023019967A2 (pt) | Composto de tetra-hidronaftaleno e método de preparação para o mesmo e uso do mesmo em medicina | |
AR127945A1 (es) | Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina | |
Esser et al. | Side effects of HIV therapy | |
BR112022014772A2 (pt) | Dispersão sólida amorfa, composição farmacêutica e processos para a preparação destas | |
CL2022003426A1 (es) | Composición farmacéutica acuosa de levilimab y su uso | |
BR112023020093A2 (pt) | Conjugado anticorpo-fármaco, incluindo anticorpo contra cldn18.2 humano, e uso do mesmo | |
MA46778A1 (fr) | Composition intranasale comprenant de la bétahistine | |
Huerta-Ramos et al. | The effect of raloxifene on symptoms and cognitive functioning in a postmenopausal schizophrenia patient: a case report | |
Rodríguez-Martínez et al. | Paliperidone extended-release: safety and tolerability from a metabolic profile perspective | |
Tanayen et al. | Antidiabetic properties of an aqueous-methanolic stem bark extract of Spathodea campanulata (Bignoniaceae) P. Beauv | |
Nowak et al. | New therapeutic strategies for Alzheimer’s disease | |
Syed et al. | Fast dispersible tablet of paroxetine hydrochloride: taste masking and administration in depressed patients |